OmniAb, Inc. (NASDAQ:OABI) Receives Consensus Recommendation of “Buy” from Analysts

OmniAb, Inc. (NASDAQ:OABI) has been assigned an average rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research note on Friday, August 11th.

Insider Activity

In other OmniAb news, CEO Matthew W. Foehr acquired 45,000 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were purchased at an average cost of $5.48 per share, for a total transaction of $246,600.00. Following the completion of the purchase, the chief executive officer now owns 2,332,919 shares in the company, valued at $12,784,396.12. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Matthew W. Foehr purchased 115,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was acquired at an average cost of $4.52 per share, with a total value of $519,800.00. Following the completion of the transaction, the chief executive officer now owns 2,574,009 shares in the company, valued at approximately $11,634,520.68. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew W. Foehr acquired 45,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was purchased at an average cost of $5.48 per share, for a total transaction of $246,600.00. Following the transaction, the chief executive officer now owns 2,332,919 shares in the company, valued at $12,784,396.12. The disclosure for this purchase can be found here. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On OmniAb

A number of hedge funds and other institutional investors have recently bought and sold shares of OABI. California State Teachers Retirement System acquired a new position in shares of OmniAb during the first quarter worth $384,000. Bank of New York Mellon Corp acquired a new position in OmniAb during the 1st quarter valued at about $1,341,000. GW&K Investment Management LLC purchased a new stake in OmniAb in the first quarter valued at about $543,000. Tower Research Capital LLC TRC acquired a new stake in OmniAb in the first quarter worth about $93,000. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of OmniAb during the first quarter valued at about $6,478,000. Hedge funds and other institutional investors own 58.73% of the company’s stock.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $5.83 on Tuesday. OmniAb has a fifty-two week low of $1.91 and a fifty-two week high of $10.50. The company has a market cap of $677.27 million, a price-to-earnings ratio of -25.35 and a beta of -0.55. The business’s 50 day moving average price is $5.32 and its 200-day moving average price is $4.38.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). The business had revenue of $6.95 million during the quarter, compared to the consensus estimate of $13.05 million. Sell-side analysts predict that OmniAb will post -0.45 earnings per share for the current year.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.